The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols
R. Beverly Raney,
Harold M. Maurer,
James R. Anderson,
Richard J. Andrassy,
Sarah S. Donaldson,
Stephen J. Qualman,
Moody D. Wharam,
Eugene S. Wiener,
William M. Crist
Affiliations
R. Beverly Raney
Department of Clinical Pediatrics, UT MD Anderson Cancer Center, Houston, Texas, USA
Harold M. Maurer
The Office of the Chancellor, University of Nebraska Medical Center, Omaha, Nebraska, USA
James R. Anderson
The Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
Richard J. Andrassy
Department of Surgery, UT MD Anderson Cancer Center, Houston, Texas, USA
Sarah S. Donaldson
The Department of Radiation Oncology, Stanford University Medical Center, Stanford, California, USA
Stephen J. Qualman
Department of Laboratory Medicine, Columbus Children's Hospital, Columbus, Ohio, USA
Moody D. Wharam
Johns Hopkins Oncology Center, Baltimore, Maryland, USA
Eugene S. Wiener
The Department of Pediatric Surgery, Pittsburgh Children's Hospital, Pittsburgh, Pennsylvania, USA
William M. Crist
Office of the Dean, University of Missouri School of Medicine, Columbia, Missouri, USA
Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomyosarcoma Study Group (IRSG, 1972–1997).
